NCT02786485View on ClinicalTrials.gov

Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
LeukemiaMyelodysplastic SyndromesLymphomasMultiple MyelomaOther High-risk Hematological Malignancies
Interventions
BIOLOGICAL

rivogenlecleucel

T cells transduced with iCasp safety switch

DRUG

Rimiducid

administered to treat GVHD

Sponsors
All Listed Sponsors
lead

Bellicum Pharmaceuticals

INDUSTRY